



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

November 30, 2023

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai – 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Intimation of retirement of Mr. Milind Patil, Chief Financial Officer of the Company.

Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We refer to our letter dated November 13, 2023, whereby an intimation was given that Mr. Milind Patil had resigned as a Director from the Board of Directors of the Company with effect from close of business on November 13, 2023 (Copy attached).

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby informs that Mr. Milind Patil, Chief Financial Officer of the Company has retired from the services of the Company effective close of business on November 30, 2023. Consequently, Mr. Patil also ceased to be a Senior Management Personnel effective the said date.

Further, the information required in terms of Regulation 30 read with Schedule III - Para A (7) of Part A of the SEBI Listing Regulations and SEBI Master Circular bearing Ref. No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, is enclosed as 'Annexure-I' to this letter.

The Company records its appreciation for the most valuable contributions rendered by Mr. Patil during his tenure.

Request you to please take the above on record.

Thanking you,

Yours truly,
For **Pfizer Limited**

Prajeet Nair
Director – Corporate Services & Company Secretary

Encl.: A/a

Annexure I

Information as required under Regulation 30 read with Schedule III - Para A of Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Retirement of Mr. Milind Patil, Chief Financial Officer from the services of the Company effective close of business on November 30, 2023 and consequently, ceased to be a Senior Management Personnel effective the said date.
2.	Date of appointment / cessation (as applicable) & term of appointment.	Cessation as the Chief Financial Officer and Senior Management Personnel of the Company effective close of business on November 30, 2023.
3.	Brief profile (in case of appointment)	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

November 13, 2023

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai – 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Intimation regarding resignation of Mr. Milind Patil as a Director from the Board.

Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby wishes to notify that Mr. Milind Patil has resigned as a Director on the Board with effect from close of business on November 13, 2023, consequent to the expiry of his 5 year term as Executive Director – Finance effective the said date and his ensuing retirement from the services of the Company effective November 30, 2023.

Pursuant to the above, Mr. Patil shall cease to be a Member of the Corporate Social Responsibility Committee, Risk Management Committee and Board Administrative & Share Transfer Committee of the Board effective close of business on November 13, 2023.

It may be noted that Mr. Patil shall continue to serve as the Chief Financial Officer of the Company until his retirement on November 30, 2023.

Further, the information required in terms of Regulation 30 read with Schedule III - Para A (7) of Part A of the SEBI Listing Regulations and SEBI Master Circular bearing Ref. No. SEBI/HO/CFD/ PoD2/CIR/P/2023/120 dated July 11, 2023, is enclosed as 'Annexure-I' to this letter.

The Company records its appreciation for the most valuable contributions rendered by Mr. Patil during his tenure.

Request you to please take the above on record.

Thanking you,

Yours truly,

For **Pfizer Limited**

PRAJEE
T NAIR

Digitally signed
by PRAJEET NAIR
Date: 2023.11.13
17:33:58 +05'30'

Prajeet Nair

Director – Corporate Services & Company Secretary

Encl.: A/a

Annexure I

**Information as required under Regulation 30 read with Schedule III - Para A of Part A of SEBI
(Listing Obligations and Disclosure Requirements) Regulations 2015**

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Resignation of Mr. Milind Patil as a Director on the Board with effect from close of business on November 13, 2023, consequent to the expiry of his 5 year term as Executive Director – Finance effective the said date and his ensuing retirement from the services of the Company effective November 30, 2023
2.	Date of appointment / cessation (as applicable) & term of appointment.	Resignation as a Director on the Board effective November 13, 2023.
3.	Brief profile (in case of appointment)	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

November 13, 2023

To,

The Board of Directors

Pfizer Limited
The Capital, 1802/1901,
Plot no. C-70, G-Block, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051

Kind Attn: Mr. Pradip Shah, Chairman

Dear Mr. Shah,

Subject: Resignation as a Director on the Board of Pfizer Limited

This is to inform you that I hereby tender my resignation as a Director on the Board with effect from close of business on November 13, 2023, consequent to the expiry of my term as an Executive Director – Finance effective the said date and my ensuing retirement from the services of the Company effective November 30, 2023.

It may be further noted that I would continue to serve the Company as the Chief Financial Officer until my retirement on November 30, 2023.

I thank the Board for the guidance and support provided to me during my tenure as an Executive Director - Finance and I wish the Company all success in times to come.

Yours Sincerely,



Milind Patil
DIN: 02546815